-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On August 10, a large number of listed pharmaceutical companies in Shenzhen Stock Exchange issued announcements, involving Huadong Medicine, Baicheng Pharmaceutical, Xinlitai, Zhongsheng Pharmaceutical, Weiming Pharmaceutical, Yunnan Baiyao, Luyan Pharmaceutical, and Asia Pacific Pharmaceutic.
, Osaikang, Livzon Group, Saisheng Pharmaceutical, Guoxin Health, Sunflower Pharmaceutical, e.
The author briefly sorted out the important announcemen.
Huadong Medicine: Net profit in the first half of the year was 34 billion yuan, a year-on-year increase of 09% According to the 2022 semi-annual report released by Huadong Medicine, the company achieved operating income of 1197 billion yuan in the first half of the year, a year-on-year increase of 93%; net profit attributable to shareholders of listed companies was 34 billion yuan, A year-on-year increase of 09%; non-net profit attributable to shareholders of listed companies was 272 billion yuan, a year-on-year increase of 5
Huadong Medicine: It is planned to acquire 60% equity of Wuhu Huaren Technology for 396 milli.
Huadong Medicine announced on the same day that the company's wholly-owned subsidiary Zhongmei Huadong will invest no more than 396 million yuan in total to obtain 60% of Huaren Technology by way of capital increase and transfer of shar.
% stake and became its controlling sharehold.
Livzon Group: Net profit in the first half of the year was 018 billion yuan, a year-on-year decrease of 2
According to the 2022 semi-annual report of Livzon Group, the company achieved an operating income of 303 billion yuan in the first half of the year, a year-on-year increase of 08%; the net profit attributable to shareholders of the listed company was 018 billion yuan Yuan, a year-on-year decrease of 23%, and earnings per share of 0900 yu.
Baicheng Pharmaceutical: Net profit in the first half of the year was 80213 million yuan, a year-on-year increase of 1062% Baicheng Pharmaceutical announced its 2022 semi-annual repo.
During the reporting period, the company achieved operating income of 246 million yuan, a year-on-year increase of 791%; net profit attributable to shareholders of listed companies 80213 million yuan, a year-on-year increase of 106
Xin Litai: Net profit in the first half of the year was 348 million yuan, a year-on-year increase of 494% According to the 2022 semi-annual report released by Xin Litai, the company achieved operating income of 668 billion yuan in the first half of the year, a year-on-year increase of 220%; the net profit attributable to shareholders of the listed company was 348 million yuan, a year-on-year increase of 494%
Guoxin Health: Net profit loss in the first half of the year was 7961 million yu.
Guoxin Health announced the 2022 semi-annual repo.
The company achieved operating income of 84025 million yuan in the first half of the year, a year-on-year increase of 557%; the net profit attributable to shareholders of the listed company was a loss of 7961 million yu.
The loss decreased by 269% year-on-ye.
Sunflower Pharmaceutical: Net profit in the first half of the year was 401 million yuan, a year-on-year increase of 35
According to the performance report of Sunflower Pharmaceutical in the first half of 2022, the company achieved a total operating income of 249 billion yuan, an increase of 01% over the same period last year; The net profit was 401 million yuan, an increase of 356% over the same period of the previous ye.
Osaikang: Fosaprepitant dimeglumine for injection was accepted for marketing application Osaikang issued a notice of acceptance of application for drug registration and marketing authorization for fosaprepitant dimglumine for injection, the announcement shows that fosaprepitant is Ari The prodrug of pitant, aprepitant inhibits emesis caused by chemotherapeutic drugs by selectively blocking NK-1 recepto.
Delayed nausea and vomiti.
The company submitted an application for drug listing registration in July 2022, which was officially accepted recent.
The PDB database shows that the sales of 150 mg of this product in Chinese sample hospitals in 2020 will be about 60 million yuan, the sales in 2021 will be nearly 260 million yuan, and the sales have exceeded 70 million yuan by the first quarter of 202Saisheng Pharmaceutical: Established Fund for Foreign Investment Saisheng Pharmaceutical announced that the Saichuang Investment Fund established by it has acquired an 18% stake in Beijing Haijing Biomedical Technology .
, L.
held by Jingyun Pharmaceutical for RMB 2 milli.
After the transfer is completed, Saichuang Investment Fund will hold a registered capital of RMB 8 million in Haijing Bio, corresponding to an 18% stake in Haijing B.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
, Osaikang, Livzon Group, Saisheng Pharmaceutical, Guoxin Health, Sunflower Pharmaceutical, e.
The author briefly sorted out the important announcemen.
Huadong Medicine: Net profit in the first half of the year was 34 billion yuan, a year-on-year increase of 09% According to the 2022 semi-annual report released by Huadong Medicine, the company achieved operating income of 1197 billion yuan in the first half of the year, a year-on-year increase of 93%; net profit attributable to shareholders of listed companies was 34 billion yuan, A year-on-year increase of 09%; non-net profit attributable to shareholders of listed companies was 272 billion yuan, a year-on-year increase of 5
Huadong Medicine: It is planned to acquire 60% equity of Wuhu Huaren Technology for 396 milli.
Huadong Medicine announced on the same day that the company's wholly-owned subsidiary Zhongmei Huadong will invest no more than 396 million yuan in total to obtain 60% of Huaren Technology by way of capital increase and transfer of shar.
% stake and became its controlling sharehold.
Livzon Group: Net profit in the first half of the year was 018 billion yuan, a year-on-year decrease of 2
According to the 2022 semi-annual report of Livzon Group, the company achieved an operating income of 303 billion yuan in the first half of the year, a year-on-year increase of 08%; the net profit attributable to shareholders of the listed company was 018 billion yuan Yuan, a year-on-year decrease of 23%, and earnings per share of 0900 yu.
Baicheng Pharmaceutical: Net profit in the first half of the year was 80213 million yuan, a year-on-year increase of 1062% Baicheng Pharmaceutical announced its 2022 semi-annual repo.
During the reporting period, the company achieved operating income of 246 million yuan, a year-on-year increase of 791%; net profit attributable to shareholders of listed companies 80213 million yuan, a year-on-year increase of 106
Xin Litai: Net profit in the first half of the year was 348 million yuan, a year-on-year increase of 494% According to the 2022 semi-annual report released by Xin Litai, the company achieved operating income of 668 billion yuan in the first half of the year, a year-on-year increase of 220%; the net profit attributable to shareholders of the listed company was 348 million yuan, a year-on-year increase of 494%
Guoxin Health: Net profit loss in the first half of the year was 7961 million yu.
Guoxin Health announced the 2022 semi-annual repo.
The company achieved operating income of 84025 million yuan in the first half of the year, a year-on-year increase of 557%; the net profit attributable to shareholders of the listed company was a loss of 7961 million yu.
The loss decreased by 269% year-on-ye.
Sunflower Pharmaceutical: Net profit in the first half of the year was 401 million yuan, a year-on-year increase of 35
According to the performance report of Sunflower Pharmaceutical in the first half of 2022, the company achieved a total operating income of 249 billion yuan, an increase of 01% over the same period last year; The net profit was 401 million yuan, an increase of 356% over the same period of the previous ye.
Osaikang: Fosaprepitant dimeglumine for injection was accepted for marketing application Osaikang issued a notice of acceptance of application for drug registration and marketing authorization for fosaprepitant dimglumine for injection, the announcement shows that fosaprepitant is Ari The prodrug of pitant, aprepitant inhibits emesis caused by chemotherapeutic drugs by selectively blocking NK-1 recepto.
Delayed nausea and vomiti.
The company submitted an application for drug listing registration in July 2022, which was officially accepted recent.
The PDB database shows that the sales of 150 mg of this product in Chinese sample hospitals in 2020 will be about 60 million yuan, the sales in 2021 will be nearly 260 million yuan, and the sales have exceeded 70 million yuan by the first quarter of 202Saisheng Pharmaceutical: Established Fund for Foreign Investment Saisheng Pharmaceutical announced that the Saichuang Investment Fund established by it has acquired an 18% stake in Beijing Haijing Biomedical Technology .
, L.
held by Jingyun Pharmaceutical for RMB 2 milli.
After the transfer is completed, Saichuang Investment Fund will hold a registered capital of RMB 8 million in Haijing Bio, corresponding to an 18% stake in Haijing B.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
